Navigation Links
Going for gold with a novel interventional radiology treatment for pancreatic cancer

TAMPA, Fla. (March 16, 2010)Pancreatic cancerknown as the most fatal cancer with no known effective treatmentrequires a radical new therapy. A promising approach may come in the form of tiny gold nanoparticlesloaded with a therapeutic agent to kill cancerin a novel procedure called "nanoembolization," said researchers at the Society of Interventional Radiology's 35th Annual Scientific Meeting in Tampa, Fla.

"As current treatments for pancreatic cancer offer minimal benefit, entirely new approaches are needed. We've developed a radically different approach that might be able to overcome some of the obstacles that have hampered previous therapies for pancreatic cancer," said Reed A. Omary, M.D., M.S., an interventional radiologist and professor of radiology and biomedical engineering and vice chair of research in the radiology department at Northwestern University in Chicago, Ill. Traditional attempts to treat this particularly horrible cancer include some combination of chemotherapy, radiation therapy, and/or surgery. However, none of these methods results in effective treatment.

Instead, Northwestern researchers constructed extremely tiny particles made out of goldtermed nanoparticleswith cancer-killing agents attached to them. These nanoparticles, which measure only 13 nanometers in diameter, are so small that 8,000 of them could be strung together and still occupy less than the width of a single human hair. In animal studies, the research team used an interventional radiology technique to inject the cancer-killing nanoparticles directly into the tumor. The investigators call this novel delivery technique "nanoembolization." Omary said, "Using nanoembolization, we dramatically increased the concentration of the nanoparticles in the tumor by 55 times over traditional methods that use a vein (such as at the elbow). That's a massive improvementand a promising discovery for this dreadful disease."

The pancreas is the organ located behind the stomach. It produces juices that help break down food and hormones that help control blood sugar levels. Pancreatic ductal adenocarcinoma is the most common type of pancreatic cancer and carries the worst prognosis of any cancer, even when diagnosed early. This aggressive cancer typically has a six-month survival rate at diagnosis. In 2009, it was estimated that more than 42,000 individuals, typically over the age of 60, were diagnosed with pancreatic cancer, making it the fourth-leading cause of cancer death in the United States. Because it is often found late and it spreads quickly, pancreatic cancer can be hard to treat.

"As current treatments offer minimal benefit, entirely new approaches are needed," said Omary, in explaining the pre-clinical study. A major reason that current pancreatic cancer treatments do not work is that scar tissue develops around the cancer. This scar tissue blocks cancer-killing drugs from entering the tumor in the first place, said Omary. "We used a catheter to deliver cancer-killing nanoparticles directly to the tumor. The catheter is placed into an artery near the groin and navigated through blood vessels to the site of the tumor, all without surgery. Once in the blood vessel that supplies the tumor, the catheter can deliver nanoparticles directly into the tumor. This method may offer a better way to overcome the scar tissue that blocks drugs from attacking the tumor," he added. With this type of catheter delivery, more drug "can go directly where we want it: to the tumor itself," said Omary. "This is not the case with injections through a vein, where the cancer-killing drug may not end up where it needs to be," he explained. The direct catheter injections also have the potential to reduce some of the side effects such as vomiting and hair loss that may be seen with typical chemotherapy. "Researchers have been using the same tool box for a long time without any benefit; it's time for us to apply some high-tech tools to treat pancreatic cancer," said Omary, the senior author of "Image-guided Nanoembolization as a Novel Local Therapy for Pancreatic Cancer: Feasibility in an Animal Model."

"For decades, interventional radiology has offered innovative ways to treat cancer patients instead of traditional surgery, chemotherapy or radiation; after all, we invented the field of minimally invasive medicine. Interventional radiologists recognize that the greatest advances in medicine occur at the interface with other medical disciplines," said Omary. "Nanoembolization is a terrific example of bringing together a diverse range of expertsin interventional radiology, chemistry and oncologyto develop a radically different method to treat the cancer with the most dismal survival rate," he added. Omary praised the efforts of all the Northwestern investigators including nanomedicine experts Chad A. Mirkin, Ph.D., director of the university's International Institute for Nanotechnology and a member of President Obama's Council of Advisors for Science and Technology, and C. Shad Thaxton, M.D., Ph.D., assistant professor of urology. Omary emphasizes that before this proposed new treatment is ready for patients, more studies will be needed to show safety and effectiveness.


Contact: Maryann Verrillo
Society of Interventional Radiology

Related biology technology :

1. YM BioSciences announces FDA clearance for two ongoing Phase II nimotuzumab trials into USA
2. New Transhumanist Magazine is Going into Print - Digital Edition is Available Now
3. European Commission Approves EFIENT(R) (prasugrel) for Patients with Acute Coronary Syndrome Undergoing PCI
4. OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer
5. BioTrends Releases TreatmentTrends(TM): US Nephrology, an Ongoing Syndicated Publication Providing Insight into Physician Perceptions and Management of Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
6. Proteolix Announces Positive Data From Two Ongoing Phase 2 Clinical Trials of Carfilzomib in Multiple Myeloma at the 50th Annual Meeting of the American Society of Hematology
7. New Program Offers Breast Cancer Clinicians and Patients Support for Pre-Operative Clinical Assessment and Ongoing Surveillance of Lymphedema
8. Alfacell Receives Going Concern Audit Opinion
9. Poniard Announces Positive Incremental Efficacy and Safety Data From Ongoing Phase 2 Picoplatin Trial in Hormone-Refractory Prostate Cancer
10. WorldHeart 10-KSB Audit Report Includes Going Concern Qualification
11. When it Comes to Going Green, These N.C. Scientists are Singing the Blues
Post Your Comments:
(Date:11/24/2015)... 2015  PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI ) ... president and chief executive officer, will present at the 27 ... New York City . The presentation will ... 2015 at 9:30 a.m. EST. and ... at least 15 minutes prior to the presentation to allow ...
(Date:11/24/2015)... According to two new studies, fewer men are having PSA ... doctors, scientists, and public health experts have been pushing for ... being done, will there be more men dying of ... "Despite the efforts made in regards to early detection for ... of death in men, killing approximately 27,500 men this year. ...
(Date:11/23/2015)... 2015 China Cord Blood Corporation (NYSE: ... of cord blood collection, laboratory testing, hematopoietic stem cell ... preliminary unaudited financial results for the second quarter and ... 2015. --> --> ... for the second quarter of fiscal 2016 increased by ...
(Date:11/23/2015)... , November 23, 2015 ... to develop daclatasvir for 112 ... countries   --> --> ... for a hepatitis C medicine, signing an agreement with Bristol-Myers ... to help cure multiple genotypes of the HCV virus.  The ...
Breaking Biology Technology:
(Date:11/10/2015)... YORK , Nov. 10, 2015 ... to behavioral biometrics that helps to identify and ... fraud. Signature is considered as the secure and ... the identification of a particular individual because each ... more accurate results especially when dynamic signature of ...
(Date:11/9/2015)... 9, 2015  Synaptics Inc. (NASDAQ: SYNA ), ... broader entry into the automotive market with a comprehensive ... pace of consumer electronics human interface innovation. Synaptics, industry-leading ... for the automotive industry and will be implemented in ... Europe , Japan , and ...
(Date:11/2/2015)...  SRI International has been awarded a contract of ... to the National Cancer Institute (NCI) PREVENT Cancer Program ... modern testing and support facilities, and analytical instrumentation to ... studies to evaluate potential cancer prevention drugs. ... Drug Development Program is an NCI-supported pipeline to bring ...
Breaking Biology News(10 mins):